Company Encyclopedia
View More
name
Cingulate
CING.US
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials. It also develops CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and mental health disorders; and plans to initiate the clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD in children, adolescents, and adults. Cingulate Inc.
4.673 T
CING.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cingulate Inc. Reinstates CEO Shane Schaffer

    Cingulate Inc. announced the reinstatement of Shane Schaffer as CEO on December 15, 2025, following the resolution of a personal legal matter. John A. Roberts remains Chairman, and Jennifer Callahan continues as CFO. The changes are effective immediately, marking the end of Schaffer's administrative leave.

    TradingView·
    US
    CING
    +5.29%
    TradingView·
    US
    CING
    +5.29%

    Cingulate Inc. Revises CEO Compensation Terms Following Administrative Leave

    Cingulate Inc. announced revisions to CEO Dr. Shane Schaffer's employment terms, effective December 15, 2025. Changes include reinstating his base salary, revising termination definitions, and adjusting severance terms. Termination for cause now requires a majority of directors, excluding Schaffer. Severance includes a lump sum of one times base salary and bonus, or 1.5 times if termination follows a change in control within 12 months.

    Reuters·
    US
    CING
    +5.29%
    Reuters·
    US
    CING
    +5.29%

    Cingulate Inc. Signs Exclusive Commercial Supply Agreement with Bend Bio Sciences

    Cingulate Inc. has signed an exclusive commercial supply agreement with Bend Bio Sciences to secure U.S. manufacturing capacity for its lead product candidate, CTx-1301. This agreement is part of Cingulate's preparation for a potential 2026 launch of CTx-1301, pending FDA approval.

    Reuters·
    US
    CING
    +5.29%
    Reuters·
    US
    CING
    +5.29%

    Cingulate Inc.’s Promising Market Position Bolstered by Strategic Partnerships and Innovative ADHD Treatment

    Wall Street analyst Naz Rahman from Maxim Group reiterated a Buy rating for Cingulate Inc., setting a price target of $8.00. The company's promising market position is supported by its strategic partnership with Indegene and the innovative ADHD treatment, CTx-1301, which is in advanced development stages. The FDA has accepted its NDA application, with a PDUFA date set for May 31, 2026. These factors, along with the hiring of Bryan Downey as Chief Commercial Officer, contribute to Rahman's optimistic outlook.

    Tip Ranks·
    US
    CING
    +5.29%
    Tip Ranks·
    US
    CING
    +5.29%

    Cingulate Inc. Reports Q3 2025 Financial Results

    Cingulate Inc. reported a Q3 net loss of $7.3 million due to increased R&D and administrative costs. Key developments include FDA acceptance of NDA for CTx-1301, $6 million financing, and Bryan Downey's appointment as Chief Commercial Officer. The company secured a $4.3 million PDUFA fee waiver and a supply agreement with Bend Bio Sciences. Positive Phase 3 results for CTx-1301 were presented, with a potential 2026 launch. Additional capital is needed for commercialization efforts.

    Tip Ranks·
    US
    CING
    +5.29%
    Tip Ranks·
    US
    CING
    +5.29%
    © 2025 Longbridge｜Disclaimer